

CLAIMS

WHAT IS CLAIMED IS:

- 5 1. A pharmaceutical formulation comprising bevacizumab, wherein the pharmaceutical formulation comprises: bevacizumab, a buffer, a stabilizer, and a surfactant, wherein
- the buffer is a histidine hydrochloride-sodium acetate buffer at a concentration of 10-30 mM;
- 10 the stabilizer is sorbitol with a content of 20-100 mg/mL; and
- the surfactant is polysorbate 80 or polysorbate 20 with a content of 0.1 mg/mL-0.5 mg/mL;
- and wherein the pH of the pharmaceutical formulation is 5.0-5.6.
- 15 2. The pharmaceutical formulation according to claim 1, wherein the concentration of the histidine hydrochloride-sodium acetate buffer is 10 mM.
3. The pharmaceutical formulation according to claim 1, wherein the surfactant is polysorbate 80 with a content of 0.1 mg/mL-0.5 mg/mL.
- 20 4. The pharmaceutical formulation according to claim 1, wherein the protein concentration of the bevacizumab is 10-100 mg/mL.
5. The pharmaceutical formulation according to claim 4, wherein the protein
- 25 concentration of the bevacizumab is 10-80 mg/mL, or the protein concentration of the bevacizumab is 10-50 mg/mL.
6. The pharmaceutical formulation according to any one of claims 1 to 5, wherein
- 30 the formulation contains: 10 mM of the histidine hydrochloride-sodium acetate buffer, 45 mg/mL of sorbitol, and 0.2 mg/mL of polysorbate 80, with a pH of 5.3.

7. The pharmaceutical formulation according to claim 6, wherein the formulation contains 10 mg/mL, 25 mg/mL, 50 mg/mL or 80 mg/mL of bevacizumab.

8. The pharmaceutical formulation according to claim 1, wherein the formulation
5 is a liquid formulation or lyophilized formulation for injection.